CELLECT is revolutionizing women’s health diagnostics with a non-invasive, accessible, and cost-effective solution. Using patented nanotechnology, CELLECT’s innovative collection device is embedded in menstrual products, capturing and stabilizing cervical cells and DNA directly from menstrual blood. This groundbreaking approach eliminates the need for invasive procedures like Pap smears, overcoming barriers of accessibility, affordability, and cultural stigma that hinder traditional screening methods. Targeting HPV and cervical cancer diagnostics as a starting point, CELLECT’s technology is designed to integrate seamlessly with existing gold-standard laboratory testing. Beyond cervical cancer, CELLECT’s platform has the potential to expand into diagnostics for other reproductive health conditions, such as endometriosis and STIs, as well as leveraging vaginal fluids for further R&D applications.